NZ718802A - Icotinib-containing topical skin pharmaceutical composition and use thereof - Google Patents
Icotinib-containing topical skin pharmaceutical composition and use thereofInfo
- Publication number
- NZ718802A NZ718802A NZ718802A NZ71880214A NZ718802A NZ 718802 A NZ718802 A NZ 718802A NZ 718802 A NZ718802 A NZ 718802A NZ 71880214 A NZ71880214 A NZ 71880214A NZ 718802 A NZ718802 A NZ 718802A
- Authority
- NZ
- New Zealand
- Prior art keywords
- icotinib
- topical
- preparations
- pharmaceutical composition
- tyrosine kinase
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title abstract 4
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 title abstract 2
- 229950007440 icotinib Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010006784 Burning sensation Diseases 0.000 abstract 1
- 206010013786 Dry skin Diseases 0.000 abstract 1
- 206010015150 Erythema Diseases 0.000 abstract 1
- 208000010201 Exanthema Diseases 0.000 abstract 1
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 208000012641 Pigmentation disease Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 206010040799 Skin atrophy Diseases 0.000 abstract 1
- 206010040868 Skin hypopigmentation Diseases 0.000 abstract 1
- 206010040880 Skin irritation Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000037336 dry skin Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 231100000321 erythema Toxicity 0.000 abstract 1
- 201000005884 exanthem Diseases 0.000 abstract 1
- 230000003425 hypopigmentation Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 208000035824 paresthesia Diseases 0.000 abstract 1
- 230000019612 pigmentation Effects 0.000 abstract 1
- 206010037844 rash Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000475 skin irritation Toxicity 0.000 abstract 1
- 230000036556 skin irritation Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013085042 | 2013-10-11 | ||
| PCT/CN2014/088344 WO2015051763A1 (zh) | 2013-10-11 | 2014-10-11 | 一种含埃克替尼的皮肤外用药物组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ718802A true NZ718802A (en) | 2017-09-29 |
Family
ID=52812537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ718802A NZ718802A (en) | 2013-10-11 | 2014-10-11 | Icotinib-containing topical skin pharmaceutical composition and use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160235757A1 (https=) |
| EP (1) | EP3056206A4 (https=) |
| JP (1) | JP6463745B2 (https=) |
| AU (1) | AU2014334222B2 (https=) |
| BR (1) | BR112016007627A2 (https=) |
| CA (1) | CA2926874C (https=) |
| HK (1) | HK1213813A1 (https=) |
| IL (1) | IL245015A0 (https=) |
| NZ (1) | NZ718802A (https=) |
| RU (1) | RU2698796C2 (https=) |
| SG (1) | SG11201602826VA (https=) |
| TW (1) | TWI630921B (https=) |
| WO (1) | WO2015051763A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102270538B1 (ko) * | 2013-06-09 | 2021-06-29 | 베타 파머수티컬 컴퍼니 리미티드 | 이코티닙 포스페이트의 신규한 다형체 형태 및 이의 용도 |
| WO2022022434A1 (zh) * | 2020-07-27 | 2022-02-03 | 杭州和正医药有限公司 | 含托法替尼药学上可接受的盐的药物组合物、制剂及应用 |
| CN116829152A (zh) * | 2021-02-02 | 2023-09-29 | 贝达药业股份有限公司 | 埃克替尼在非小细胞肺癌术后辅助治疗中的应用 |
| CN116492293A (zh) * | 2022-01-25 | 2023-07-28 | 杭州和正医药有限公司 | 一种含托法替尼的局部用药的药物组合物、制剂及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0618933A2 (pt) * | 2005-11-24 | 2016-09-13 | Basf Se | método para produzir uma molécula efetora que se liga à queratina, molécula efetora que se liga à queratina, uso das moléculas efetoras que se ligam à queratina, composto, e, dermocosmético |
| FR2909284B1 (fr) * | 2006-11-30 | 2012-09-21 | Galderma Sa | Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien |
| EP2392576B1 (en) | 2008-07-08 | 2016-02-17 | Beta Pharma, Inc. | Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof |
| GB201010954D0 (en) * | 2010-06-29 | 2010-08-11 | Edko Pazarlama Tanitim Ticaret | Compositions |
| MX2013004296A (es) * | 2010-10-21 | 2013-09-26 | Cadila Healthcare Ltd | Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis. |
-
2014
- 2014-10-11 SG SG11201602826VA patent/SG11201602826VA/en unknown
- 2014-10-11 WO PCT/CN2014/088344 patent/WO2015051763A1/zh not_active Ceased
- 2014-10-11 US US15/028,118 patent/US20160235757A1/en not_active Abandoned
- 2014-10-11 AU AU2014334222A patent/AU2014334222B2/en not_active Ceased
- 2014-10-11 RU RU2016118063A patent/RU2698796C2/ru not_active IP Right Cessation
- 2014-10-11 BR BR112016007627A patent/BR112016007627A2/pt not_active IP Right Cessation
- 2014-10-11 HK HK16101922.3A patent/HK1213813A1/zh unknown
- 2014-10-11 JP JP2016521612A patent/JP6463745B2/ja not_active Expired - Fee Related
- 2014-10-11 EP EP14851908.5A patent/EP3056206A4/en not_active Withdrawn
- 2014-10-11 CA CA2926874A patent/CA2926874C/en not_active Expired - Fee Related
- 2014-10-11 NZ NZ718802A patent/NZ718802A/en not_active IP Right Cessation
- 2014-10-13 TW TW103135438A patent/TWI630921B/zh not_active IP Right Cessation
-
2016
- 2016-04-10 IL IL245015A patent/IL245015A0/en unknown
-
2019
- 2019-04-30 US US16/398,827 patent/US20190321369A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3056206A4 (en) | 2017-07-05 |
| SG11201602826VA (en) | 2016-05-30 |
| JP6463745B2 (ja) | 2019-02-06 |
| IL245015A0 (en) | 2016-05-31 |
| WO2015051763A1 (zh) | 2015-04-16 |
| AU2014334222B2 (en) | 2017-03-09 |
| RU2698796C2 (ru) | 2019-08-30 |
| CA2926874A1 (en) | 2015-04-16 |
| CA2926874C (en) | 2018-12-11 |
| US20190321369A1 (en) | 2019-10-24 |
| AU2014334222A1 (en) | 2016-05-05 |
| EP3056206A1 (en) | 2016-08-17 |
| TW201513894A (zh) | 2015-04-16 |
| RU2016118063A (ru) | 2017-11-16 |
| BR112016007627A2 (pt) | 2017-08-01 |
| JP2016532659A (ja) | 2016-10-20 |
| TWI630921B (zh) | 2018-08-01 |
| US20160235757A1 (en) | 2016-08-18 |
| HK1213813A1 (zh) | 2016-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391180B (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo | |
| BR112016000561B8 (pt) | Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma | |
| MX373042B (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| MX349594B (es) | Composicion para uso cosmetico adecuada para producir un efecto de pigmentacion sobre el cabello. | |
| MX361590B (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
| MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| HK1207069A1 (en) | Heterocyclic compounds and uses thereof | |
| MX2021013139A (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| TW201613577A (en) | Pharmaceutical combinations | |
| BR112013024824A2 (pt) | ésteres isopentílicos para uso em composições cosméticas, dermatológicas ou farmacêuticas | |
| EA201690077A1 (ru) | Терапевтически активные производные эстратриен-тиазола | |
| BR112015027436A2 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| NZ759173A (en) | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments | |
| NZ718802A (en) | Icotinib-containing topical skin pharmaceutical composition and use thereof | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| MX379253B (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| SA516370446B1 (ar) | تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها | |
| PH12016500120A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| BR112017013208A2 (pt) | uso de octenidina | |
| MX2015014905A (es) | Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos. | |
| PH12015502420A1 (en) | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2019 BY ACUMASS Effective date: 20180918 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2020 BY ACUMASS Effective date: 20190917 |
|
| LAPS | Patent lapsed |